Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Equillium, Inc.NASDAQ: EQ
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $5.59M fell 37.0% year over year, ahead of the -54.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 41.8% from the prior quarter. Over 3 fiscal years it compounded at -32.8% a year.
Context
- Operating expenses increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -37.0% holds above the trailing-twelve-month pace of -54.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 23.63M USD
- Year-over-year change
- -52.1%
- 4-year CAGR
- -11.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.63M | -52.1% |
| FY2024 | 2024-12-31 | 49.36M | -2.5% |
| FY2023 | 2023-12-31 | 50.61M | -35.0% |
| FY2022 | 2022-12-31 | 77.84M | +106.0% |
| FY2021 | 2021-12-31 | 37.79M | — |
Operating Expenses vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 operating expenses of $20.3M is the 7th highest of the 10 companies compared; the peer median is $34.01M.
- Its year-over-year change of -54.6% is the lowest of 10, against a peer median of -22.3%.
- Over three fiscal years its annual growth of -32.8% compares with a peer median of -7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $98.5M | -27.0% | -23.2% | 148.9% | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Mar 2026 | $52.24M | +6.3% | -0.3% | 159.6% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $33.51M | +199.7% | +85.4% | — |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $14.13M | +26.1% | -25.3% | 999.7% | |
| LTM Mar 2026 | $9.39M | -25.3% | +131.1% | — | |
| Peer median (excluding EQ) | $34.01M | -22.3% | -7.2% | 786.8% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15.76M | 36.08M | 41.1M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 116K |
| Gross Profit | 0 | 15.76M | 36.08M | 41.1M | (116K) |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 26.38M | 37.55M | 37.04M | 37.43M | 12.84M |
| Selling, General & Admin | 11.41M | 17.24M | 13.57M | 11.94M | 10.79M |
| Operating Expenses | 37.79M | 77.84M | 50.61M | 49.36M | 23.63M |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| EBITDA | (37.91M) | (61.26M) | (12.14M) | (7.57M) | (22.28M) |
| EBITDA Margin | — | -388.7% | -33.6% | -18.4% | — |
| Operating Income | (37.79M) | (62.08M) | (14.52M) | (8.27M) | (23.63M) |
| Operating Margin | — | -393.9% | -40.2% | -20.1% | — |
| Interest Income | 57K | 420K | 2.33M | 1.38M | 833K |
| Interest Expense | 1.07M | 1.05M | 491K | 0 | 0 |
| Other Income / Expenses | (1.27M) | (352K) | 1.77M | 563K | 1.24M |
| Income Before Tax | (39.05M) | (62.43M) | (12.76M) | (7.71M) | (22.4M) |
| Pre-Tax Margin | — | -396.1% | -35.3% | -18.8% | — |
| Income Tax Expense | 0 | 0 | 580K | 361K | 0 |
| Net Income | (38.98M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Net Margin | — | -396.1% | -37.0% | -19.6% | — |
| EPS (Basic) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| EPS (Diluted) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| Weighted Avg Shares | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
| Weighted Avg Shares (Diluted) | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.